MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks.
Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025.
Copyright: nicoletaionescu / 123RF Stock Photo
To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets.
While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Pandemic housing boom tightness fades as housing market lot supply rises
Want more housing market stories from Lance Lambert's ResiClub in your inbox? Subscribe to the ResiClub newsletter. Employers need help managing workers who are taking second jobs New study finds coffee is good for you, but there's a catch The FDA is warning you not to use this cookware—it could be poisoning your food with lead Shop Top Mortgage Rates Your Path to Homeownership A quicker path to financial freedom Personalized rates in minutes During the pandemic housing boom, we saw red-hot housing demand quickly absorb much of the available slack in the housing market. Back in 2021, active housing inventory for sale, unsold completed new builds, and available lot supply all plunged to historic lows. But ever since the pandemic housing boom fizzled out in mid-2022, housing slack has been building back up in the housing market—especially in certain pockets of the Sun Belt and Mountain West. Look no further than Zonda's 'New Home Lot Supply Index,' which measures lot supply based on the number of single-family vacant developed lots and the rate at which those lots are absorbed via housing starts. A higher index value indicates a greater supply of single-family vacant developed lots, while a lower index value indicates a tighter lot supply/new construction market. That index in Q2 2025 climbed to 68.4—well above the all-time low of 35.8 set at the height of the pandemic housing boom in Q2 2022, when builders were buying as much entitled land as they could find. 'The timing of land and lot deliveries is a growing challenge in today's housing market,' wrote Zonda chief economist Ali Wolf on August 12. 'While builders had planned to increase housing starts in 2025, they slowed production as the year progressed due to choppy consumer demand and rising resale supply. This slower pace of construction contributed to the five-year high in Zonda's Lot Supply Index, as fewer lots were converted into starts.' According to Zonda, homebuilder lot supply loosened/rose in 22 of the 30 major metro-area housing markets tracked over the past 12 months. Housing markets like Tampa, Florida; Austin; Nashville; and Charlotte, North Carolina, experienced some of the most significant year-over-year loosening of lot supply. That said, despite an uptick in available lots in some markets on a year-over-year basis, most housing markets are still what Zonda considers 'significantly undersupplied.' Zonda's New Home Lot Supply Index has five groupings: 'significantly oversupplied' = plus 125 score 'slightly oversupplied' = 115 to 124 score 'appropriately supplied' = 85 to 114 score 'slightly undersupplied' = 75 to 84 score 'significantly undersupplied' = below 75 score According to Zonda, three major metro-area housing markets now are 'appropriately supplied' for lot/land supply: Austin, Atlanta, and Dallas. Note: If Zonda had analyzed more than 30 markets, the count would likely have been higher than just three—especially in some softer pockets of Southwest Florida. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
5 High-Quality Dividend Stocks Yielding Well Over 5% to Buy Without Hesitation Right Now
Key Points Brookfield Infrastructure Partners and MPLX offer high yields due in part to their tax complications. EPR Properties, Main Street Capital, and Realty Income pay monthly dividends. These companies all expect to continue increasing their high-yielding dividends in the future. 10 stocks we like better than Realty Income › With the market continuing its upward move this year, dividend yields have continued to fall. The S&P 500's yield is around 1.2%, near its lowest level in over two decades. However, several stocks still offer attractive dividend yields. Here are five high-quality dividend stocks with yields well over 5%. Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) currently yields around 5.8%, which is higher than the yield of its economically equivalent corporate twin, Brookfield Infrastructure Corporation (NYSE: BIPC), at 4.4%. While both entities provide investors with access to Brookfield's global infrastructure assets, BIP offers a higher payout due to its partnership structure and because it sends investors a Schedule K-1 federal tax form, which can complicate tax returns. BIPC, in contrast, delivers a lower yield but issues a 1099-DIV, a simpler tax report for investors. The global infrastructure operator generates stable cash flow. About 85% of its funds from operations (FFO) comes from long-term contracts or regulated frameworks. Meanwhile, Brookfield pays out a conservative portion of its stable cash flow in dividends (60%-70%). It also has a solid investment-grade balance sheet. Those features give it the flexibility to continue investing in growing its business. Brookfield expects to deliver FFO per share growth of 10% or more, fueled by inflation-driven rate increases, expansion projects, and acquisitions. This easily supports its plan to provide annual dividend increases of 5% to 9% over the long term, further extending its 16-year growth streak. EPR Properties EPR Properties (NYSE: EPR) currently yields 6.7%. The real estate investment trust (REIT) pays its dividends monthly, making it highly attractive for those seeking a lucrative passive income stream. The REIT focuses on investing in experiential real estate such as movie theaters, eat & play venues, attractions, and fitness and wellness properties. It leases these properties back to operating tenants under long-term, primarily triple net agreements (NNN). Those leases provide it with predictable rental income to cover its high-yielding dividend. EPR Properties utilizes a combination of excess cash flow generated after paying dividends, noncore property sales, and balance sheet capacity to invest in additional experiential properties. It aims to invest between $200 million and $300 million annually in acquisitions, development projects, and redevelopments. This investment rate should grow its income per share by 3% to 4% annually, supporting a similar dividend growth rate. Main Street Capital Main Street Capital (NYSE: MAIN) is a business development company (BDC) with a rather unique dividend policy. It pays a monthly dividend set at a sustainable level, allowing investors to receive a recurring income stream they can count on. It has never decreased or suspended this payment. Instead, it has raised it by a cumulative 132% since going public in late 2007. Additionally, Main Street periodically pays a supplemental quarterly dividend. The company's most recent payments gave it a 6.6% yield. The BDC supports its dividend payments with a portfolio of debt and equity investments that generate interest and dividend income. The company sets its monthly dividend below its expected income to enhance durability. It also maintains an investment-grade credit rating. Main Street Capital uses its financial flexibility to make more income-generating investments, enabling it to steadily increase its monthly dividend and provide higher supplemental payments. MPLX MPLX (NYSE: MPLX) is a master limited partnership (MLP), similar in structure to Brookfield Infrastructure Partners. Like Brookfield, MPLX also sends a Schedule K-1 tax form to its investors, which affects tax reporting. The energy midstream company yields more than 7.5%. The MLP generates stable cash flow backed by long-term contracts and regulated rate structures. MPLX currently produces enough cash to cover its lucrative distribution by 1.5 times. That allows it to retain cash to fund expansion projects while maintaining its strong financial profile. It currently has a 3.1 times leverage ratio, well below the 4.0x range its stable cash flows can support. MPLX recently agreed to acquire Northwind Midstream in a $2.4 billion deal and has multiple organic projects slated to start commercial service through the end of the decade. These growth investments should support continued distribution increases, building on its history of annual payout raises since 2012 and a compound annual distribution growth rate above 10% since 2021. Realty Income Realty Income (NYSE: O) currently yields more than 5.5%. The REIT owns a diversified portfolio of commercial real estate (retail, industrial, gaming, and other properties such as data centers) net leased to many of the world's leading companies. That lease structure provides it with very stable rental income because tenants cover all property operating expenses. The company pays out a conservative portion of its stable income in dividends (around 75% of its adjusted FFO). Realty Income has increased its dividend 131 times since its public market listing in 1994 (including the last 111 quarters in a row). That steady growth should continue as the REIT acquires more income-producing real estate. With one of the strongest financial profiles in the industry and $14 trillion of real estate suitable for net leases, Realty Income has plenty of room to continue expanding. Great high-yielding dividend stocks to buy for income These five companies have excellent dividend-paying track records. That's due in part to their stable and growing cash flows, as well as their strong financial profiles. With these strengths, they should be able to continue growing their high-yielding payouts well into the future. If you're looking to boost your income and build a solid foundation for your portfolio, these dividend stocks are great ones to consider buying and holding for the long term. Should you invest $1,000 in Realty Income right now? Before you buy stock in Realty Income, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Realty Income wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Matt DiLallo has positions in Brookfield Infrastructure, Brookfield Infrastructure Partners, EPR Properties, Main Street Capital, and Realty Income. The Motley Fool has positions in and recommends EPR Properties and Realty Income. The Motley Fool recommends Brookfield Infrastructure Partners. The Motley Fool has a disclosure policy. 5 High-Quality Dividend Stocks Yielding Well Over 5% to Buy Without Hesitation Right Now was originally published by The Motley Fool Inicia sesión para acceder a tu cartera de valores
Associated Press
3 hours ago
- Associated Press
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855
